Pre-Clinical Evaluation of the Nanoliposomal antiPCSK9 Vaccine in Healthy Non-Human Primates
出版年份 2021 全文链接
标题
Pre-Clinical Evaluation of the Nanoliposomal antiPCSK9 Vaccine in Healthy Non-Human Primates
作者
关键词
-
出版物
Vaccines
Volume 9, Issue 7, Pages 749
出版商
MDPI AG
发表日期
2021-07-07
DOI
10.3390/vaccines9070749
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- PCSK9 vaccine: so near, yet so far!
- (2021) Amirhossein Sahebkar et al. EUROPEAN HEART JOURNAL
- Novel Treatment Strategies for Secondary Prevention of Cardiovascular Disease: A Systematic Review of Cost-Effectiveness
- (2020) Clara Marquina et al. PHARMACOECONOMICS
- Monocyte Chemoattractant Protein 1 Promotes VEGF-A Expression in OSCC by Activating ILK and MEK1/2 Signaling and Downregulating miR-29c
- (2020) Ming-Yu Lien et al. Frontiers in Oncology
- Long-term generation of antiPCSK9 antibody using a nanoliposome-based vaccine delivery system
- (2019) Amir Abbas Momtazi-Borojeni et al. ATHEROSCLEROSIS
- PCSK9 hapten multicopy displayed onto Carrier Protein nanoparticle: an anti-atherosclerosis vaccine
- (2019) Shasha You et al. ACS Biomaterials-Science & Engineering
- PCSK9 and inflammation: a review of experimental and clinical evidence
- (2019) Amir Abbas Momtazi-Borojeni et al. European Heart Journal-Cardiovascular Pharmacotherapy
- The how’s and what’s of vaccine reactogenicity
- (2019) Caroline Hervé et al. npj Vaccines
- P704Nanoliposomal anti-PCSK9 vaccine ameliorates glucose intolerance and insulin resistance in diabetic rats
- (2019) A A Momtazi-Borojeni et al. EUROPEAN HEART JOURNAL
- P6195Nanoliposomal anti-PCSK9 vaccine induces long-term and safe protection against atherosclerosis in C57BL/6 mouse
- (2019) A A Momtazi-Borojeni et al. EUROPEAN HEART JOURNAL
- P6194Therapeutic effect of nanoliposomal anti-PCSK9 vaccine on hypercholesterolemia and atherosclerosis in C57BL/6 mice
- (2019) A A Momtazi-Borojeni et al. EUROPEAN HEART JOURNAL
- Therapeutic effect of nanoliposomal PCSK9 vaccine in a mouse model of atherosclerosis
- (2019) Amir Abbas Momtazi-Borojeni et al. BMC Medicine
- Vaccine Against PCSK9 Improved Renal Fibrosis by Regulating Fatty Acid β‐Oxidation
- (2019) Danyu Wu et al. Journal of the American Heart Association
- What have we learned about lipids and cardiovascular risk from PCSK9 inhibitor outcomes trials?
- (2018) Maciej Banach et al. CARDIOVASCULAR RESEARCH
- The AT04A vaccine against proprotein convertase subtilisin/kexin type 9 reduces total cholesterol, vascular inflammation, and atherosclerosis in APOE*3Leiden.CETP mice
- (2017) Christine Landlinger et al. EUROPEAN HEART JOURNAL
- Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease
- (2017) Marc S. Sabatine et al. NEW ENGLAND JOURNAL OF MEDICINE
- A Therapeutic Peptide Vaccine Against PCSK9
- (2017) Yajie Pan et al. Scientific Reports
- Effect of Evolocumab on Progression of Coronary Disease in Statin-Treated Patients
- (2016) Stephen J. Nicholls et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Cost-effectiveness of PCSK9 Inhibitor Therapy in Patients With Heterozygous Familial Hypercholesterolemia or Atherosclerotic Cardiovascular Disease
- (2016) Dhruv S. Kazi et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Potential Use of Salivary Markers for Longitudinal Monitoring of Inflammatory Immune Responses to Vaccination
- (2016) Pei Wen Lim et al. MEDIATORS OF INFLAMMATION
- Efficacy and Safety of Alirocumab in Reducing Lipids and Cardiovascular Events
- (2015) Jennifer G. Robinson et al. NEW ENGLAND JOURNAL OF MEDICINE
- Efficacy and Safety of Evolocumab in Reducing Lipids and Cardiovascular Events
- (2015) Marc S. Sabatine et al. NEW ENGLAND JOURNAL OF MEDICINE
- A cholesterol-lowering VLP vaccine that targets PCSK9
- (2015) Erin Crossey et al. VACCINE
- Peptide-Based Anti-PCSK9 Vaccines - An Approach for Long-Term LDLc Management
- (2014) Gergana Galabova et al. PLoS One
- The safety of therapeutic monoclonal antibodies: Implications for cardiovascular disease and targeting the PCSK9 pathway
- (2013) A.L. Catapano et al. ATHEROSCLEROSIS
- New Therapies Targeting apoB Metabolism for High-Risk Patients with Inherited Dyslipidaemias: What Can the Clinician Expect?
- (2013) Amirhossein Sahebkar et al. CARDIOVASCULAR DRUGS AND THERAPY
- Genetics: A gene of rare effect
- (2013) Stephen S. Hall NATURE
- PCSK9 Inhibitors: Potential in Cardiovascular Therapeutics
- (2013) Rose Q. Do et al. Current Cardiology Reports
- How Do We Improve Patient Compliance and Adherence to Long-Term Statin Therapy?
- (2012) Patricia Maningat et al. Current Atherosclerosis Reports
- Suppression of Vaccine Immunity by Inflammatory Monocytes
- (2012) L. A. Mitchell et al. JOURNAL OF IMMUNOLOGY
- Immunization against proprotein convertase subtilisin-like/kexin type 9 lowers plasma LDL-cholesterol levels in mice
- (2012) Elena Fattori et al. JOURNAL OF LIPID RESEARCH
- Development of Antidrug Antibodies Against Adalimumab and Association With Disease Activity and Treatment Failure During Long-term Follow-up
- (2011) Geertje M. Bartelds JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Genetic and Metabolic Determinants of Plasma PCSK9 Levels
- (2009) Susan G. Lakoski et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Development of AFFITOPE vaccines for Alzheimer’s disease (AD) — From concept to clinical testing
- (2009) A. Schneeberger et al. Journal of Nutrition Health & Aging
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started